Stock Track | Verona Pharma Plunges 5.95% Despite Analyst Expectations of Profitability in 2026

Stock Track

Jan 10, 2025

Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.

The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.

However, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1114945431"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114945431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114945431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114945431","market":"us","top_or_hot":-1,"title":"Stock Track | Verona Pharma Plunges 5.95% Despite Analyst Expectations of Profitability in 2026","media":"Stock Track","content":"<p>Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.</p>\n\n<p>The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.</p>\n\n<p>However, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Plunges 5.95% Despite Analyst Expectations of Profitability in 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Plunges 5.95% Despite Analyst Expectations of Profitability in 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-10 23:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.</p>\n\n<p>The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.</p>\n\n<p>However, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"","article_id":"1114945431","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114945431","pubTimestamp":1736523378,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Verona Pharma plc , a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"尽管分析师预计维罗纳制药(Verona Pharma)将于2026年实现盈利，但股价仍暴跌5.95%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.\nThe stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.\nHowever, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}